Greg Raskin: I’d lucked upon a dream job at MSK
Greg Raskin, Senior Vice President, Technology Development at Memorial Sloan Kettering Cancer Center, posted the following on LinkedIn:
“When I joined MSK in 2012, I’d lucked upon a dream job.
With a background as a biotech and life science investor for many years – and briefly as a management consultant and physician before that – I now got the chance to integrate my prior experiences in business, science and medicine, joining the leadership of what I think is the finest cancer center in all the land.
My intuition about this job was right. I feel grateful and fortunate to have spent these past dozen years working to identify, develop and commercialize new treatments for cancer patients as the leader of MSK’s Office of Technology Development.
Along the way, our team built companies, sped treatments into clinical trials, and launched a few new medicines to treat some of the toughest cancers. I’m especially proud that we brought in over $1.5 billion in licensing revenue to MSK during this time, a figure which ranks in the top five among all US universities and academic medical centers. That money has gone back into cancer research at MSK, including through OTD’s own Technology Development Fund that I was honored to lead.
Now, it’s time to pursue a new dream. In late October, I’ll leave MSK and OTD due to internal structural changes. I’m very happy to report that the team will be in excellent hands under the leadership of my dear friend and colleague, Dr. Yashodhara Dash.
Before I decide on my next move, I’m seizing the moment to take some time off, invigorated by something rare in our busy lives – a blank slate. I look forward to staying in touch, so don’t be a stranger!”
Source: Greg Raskin/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023